Compare 10X Genomics Inc (TXG) vs Visa Inc (V) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
10X Genomics Inc vs Visa Inc — how do they compare? 10X Genomics Inc trades at $81 (market cap $10.07B), while Visa Inc trades at $385.6 (market cap $704.20B). The key difference: Visa Inc is far larger — about 69.9× 10X Genomics Inc's market cap, and Visa Inc pays a 0.71% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold 10X Genomics Inc for 91 Days and Visa Inc for 115 Days on average.
| TXG | V | |
|---|---|---|
Market Cap | $10.07B | $704.20B |
Volume | 5,657,286 | 6,405,857 |
Sector | Health | Financials |
52-Week High | $97.74 | $384.14 |
52-Week Low | $11.48 | $295.52 |
Typical Hold Time | 91 Days | 115 Days |
Enterprise Value | $9.59B | $714.78B |
Dividend Yield | — | 0.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TXG trades at $80.65, up 5.98% on the day, showing strong recent momentum despite a bearish technical signal. The company reported revenue of $642.82M for 2025 with a gross margin of 70.03%, but remains unprofitable with a net loss of $43.54M. Recent news highlights the launch of the Atera spatial biology platform and a patent victory, signaling innovation and competitive strength. Analyst consensus is mixed with a $74.30 price target below the current price, indicating caution on valuation.
The outlook for TXG hinges on commercial execution of new products like Atera to drive revenue growth and a path to profitability. Investment opportunity lies in its leading technology platform and expanding market demand in genomics. Key risks include persistent losses, high valuation multiples, and competitive pressures in the life sciences tools sector. The stock's recent rally faces a test near technical resistance at $81.
Visa (V) trades at $385.45, up 3.59% today, with a bullish technical signal and strong analyst consensus. The stock shows robust fundamentals, including a 50.78% net income margin and consistent earnings beats. Recent news highlights Visa's AI-driven initiatives like Intelligent Commerce Connect and partnerships to advance stablecoin adoption, positioning it for future growth in digital payments.
Outlook remains positive with a consensus price target of $422.24, implying 9.5% upside. Risks include competitive fintech threats and regulatory pressures. The company's high profitability and strategic focus on AI and digital payments support long-term investment appeal, though valuation multiples are elevated.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
